The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst)
 
Jonathan W. Lee
No Relationships to Disclose
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Halozyme; Halozyme; Halozyme; Halozyme; Merck; Merck; Merck; Merck; Newlink Genetics/Pharmatech; Newlink Genetics/Pharmatech; Newlink Genetics/Pharmatech; Newlink Genetics/Pharmatech; Oncomed; Oncomed; Oncomed; Oncomed; Seagen; Seagen; Seagen; Seagen
 
Marinela Capanu
No Relationships to Disclose
 
Jennifer Park
No Relationships to Disclose
 
Talia Golan
Honoraria - MSD; MSD; MSD; MSD; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst)
 
Esther Tahover
No Relationships to Disclose
 
Maeve Aine Lowery
Consulting or Advisory Role - Agios; Agios; Agios; Agios; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Travel, Accommodations, Expenses - Ipsen; Ipsen; Ipsen; Ipsen
 
Joanne F. Chou
No Relationships to Disclose
 
Vaibhav Sahai
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Incyte; Incyte; Incyte; Incyte; Ipsen; Ipsen; Ipsen; Ipsen; Klus Pharma; Klus Pharma; Klus Pharma; Klus Pharma; Newlink Genetics; Newlink Genetics; Newlink Genetics; Newlink Genetics; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics
Research Funding - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); FibroGen (Inst); FibroGen (Inst); FibroGen (Inst); FibroGen (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Rafael Pharmaceuticals (Inst); Rafael Pharmaceuticals (Inst); Rafael Pharmaceuticals (Inst); Rafael Pharmaceuticals (Inst)
 
Robin Brenner
No Relationships to Disclose
 
Hedy L. Kindler
Consulting or Advisory Role - Aldeyra Therapeutics; Aldeyra Therapeutics; Aldeyra Therapeutics; Aldeyra Therapeutics; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; ipsen; ipsen; ipsen; ipsen; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Merck; Merck; Merck; Merck; Paradox Therapeutics; Paradox Therapeutics; Paradox Therapeutics; Paradox Therapeutics
Research Funding - Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Deciphera (Inst); Deciphera (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Inhibrx (Inst); Inhibrx (Inst); Inhibrx (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Polaris (Inst); Polaris (Inst); Polaris (Inst); Polaris (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst); Verastem (Inst)
 
Kenneth H. Yu
Consulting or Advisory Role - celgene; celgene; celgene; celgene; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merrimack; Merrimack; Merrimack; Merrimack
 
Alice Zervoudakis
No Relationships to Disclose
 
Shreya Vemuri
No Relationships to Disclose
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Adverum (I); Adverum (I); Adverum (I); Alimera Sciences (I); Alimera Sciences (I); Alimera Sciences (I); Alimera Sciences (I); Allergan (I); Allergan (I); Allergan (I); Allergan (I); Biomarin (I); Biomarin (I); Biomarin (I); Biomarin (I); Fortress Biotech (I); Fortress Biotech (I); Fortress Biotech (I); Fortress Biotech (I); Genentech/Roche (I); Genentech/Roche (I); Genentech/Roche (I); Genentech/Roche (I); Novartis (I); Novartis (I); Novartis (I); Novartis (I); Optos (I); Optos (I); Optos (I); Optos (I); Regeneron (I); Regeneron (I); Regeneron (I); Regeneron (I); Regenxbio (I); Regenxbio (I); Regenxbio (I); Regenxbio (I); Spark Therapeutics (I); Spark Therapeutics (I); Spark Therapeutics (I); Spark Therapeutics (I)
 
Richard K. G. Do
Honoraria - ALK (I); ALK (I); ALK (I); ALK (I); Bayer; Bayer; Bayer; Bayer
Consulting or Advisory Role - DBV Technologies (I); DBV Technologies (I); DBV Technologies (I); DBV Technologies (I)
Patents, Royalties, Other Intellectual Property - UptoDate chapters on Food Allergy (I); UptoDate chapters on Food Allergy (I); UptoDate chapters on Food Allergy (I); UptoDate chapters on Food Allergy (I)
 
Neesha C. Dhani
Honoraria - Celgene; Celgene; Celgene; Celgene; Sanofi; Sanofi; Sanofi; Sanofi
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Incyte; Incyte; Incyte; Incyte
 
Alice P. Chen
No Relationships to Disclose
 
David Paul Kelsen
Consulting or Advisory Role - Kitov Pharmaceuticals; Kitov Pharmaceuticals; Kitov Pharmaceuticals; Kitov Pharmaceuticals; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Steba Biotech; Steba Biotech; Steba Biotech; Steba Biotech
Patents, Royalties, Other Intellectual Property - Use of Iron Containing Particles for Imaging by MRI; Use of Iron Containing Particles for Imaging by MRI; Use of Iron Containing Particles for Imaging by MRI; Use of Iron Containing Particles for Imaging by MRI